Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $43 to $45.
April 12, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson reaffirmed an Outperform rating on Revolution Medicines and increased the price target from $43 to $45.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100